US Patent No: 7,749,542

Number of patents in Portfolio can not be more than 2000

Opioid agonist/antagonist combinations

Stats

ALSO PUBLISHED AS: 20080292694
See full text
ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
PURDUE PHARMA L.P.STAMFORD, CT252

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Colucci, Robert D Newtown, CT 21 569
Kaiko, Robert F Weston, CT 44 963

Cited Art Landscape

Patent Info (Count) # Cites Year
 
PURDUE PHARMA L.P. (39)
4,828,836 Controlled release pharmaceutical composition 147 1987
4,834,985 Controlled release pharmaceutical composition 176 1987
4,990,341 Controlled release hydromorphone composition 99 1989
5,266,331 Controlled release oxycodone compositions 109 1991
5,273,760 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 150 1991
5,286,493 Stabilized controlled release formulations having acrylic polymer coating 148 1992
5,549,912 Controlled release oxycodone compositions 101 1993
5,472,712 Controlled-release formulations coated with aqueous dispersions of ethylcellulose 132 1993
5,478,577 Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level 111 1993
5,411,745 Powder-layered morphine sulfate formulations 75 1994
5,965,161 Extruded multi-particulates 82 1994
5,639,476 Controlled release formulations coated with aqueous dispersions of acrylic polymers 291 1995
5,508,042 Controlled release oxycodone compositions 103 1995
5,968,551 Orally administrable opioid formulations having extended duration of effect 113 1995
5,958,459 Opioid formulations having extended controlled released 71 1995
5,656,295 Controlled release oxycodone compositions 88 1996
5,681,585 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 72 1996
5,672,360 Method of treating pain by administering 24 hour oral opioid formulations 113 1996
6,143,322 Method of treating humans with opioid formulations having extended controlled release 80 1997
5,958,452 Extruded orally administrable opioid formulations 103 1997
5,968,547 Method of providing sustained analgesia with buprenorphine 61 1997
6,077,533 Powder-layered oral dosage forms 47 1998
6,228,863 Method of preventing abuse of opioid dosage forms 94 1998
6,277,384 Opioid agonist/antagonist combinations 69 1998
6,103,261 Opioid formulations having extended controlled release 75 1999
6,335,033 Melt-extrusion multiparticulates 53 1999
6,261,599 Melt-extruded orally administrable opioid formulations 85 1999
6,294,195 Orally administrable opioid formulations having extended duration of effect 78 1999
6,375,957 Opioid agonist/opioid antagonist/acetaminophen combinations 86 2000
6,696,088 Tamper-resistant oral opioid agonist formulations 73 2001
6,475,494 Opioid agonist/antagonist combinations 50 2001
2003/0069,263 Pharmaceutical combinations of oxycodone and naloxone 34 2002
2003/0073,714 Opioid agonist formulations with releasable and sequestered antagonist 37 2002
6,696,066 Opioid agonist/antagonist combinations 63 2002
2003/0229,111 Naltrexone hydrochloride compositions 12 2003
2004/0186,121 Tamper-resistant oral opioid agonist formulations 29 2003
7,172,767 Opioid agonist / antagonist combinations 34 2003
2006/0182,801 Sequestered antagonist formulations 28 2006
7,419,686 Opioid agonist/antagonist combinations 17 2006
 
EURO-CELTIQUE S.A. (35)
4,366,310 Controlled release compositions 38 1980
4,940,587 Oral pharmaceutical composition through mucosa 90 1986
4,844,907 Pharmaceutical composition comprising analgesic and anti-inflammatory agent 111 1986
4,834,965 Controlled release pharmaceutical composition 68 1987
4,867,985 Spheroids 73 1988
5,071,646 Pharmaceutical ion exchange resin composition 90 1989
5,091,189 Controlled release dosage forms having a defined water content 34 1991
5,215,758 Controlled release matrix suppository for pharmaceuticals 66 1991
5,324,351 Aqueous dispersions of zein and preparation thereof 76 1992
5,356,467 Controlled release coatings derived from aqueous dispersions of zein 112 1993
5,500,227 Immediate release tablet cores of insoluble drugs having sustained-release coating 117 1993
5,622,722 Spheroid formulation 33 1994
5,508,043 Controlled release matrix for pharmaceuticals 40 1995
5,670,172 Pharmaceutical spheroid formulation 56 1995
6,024,982 Immediate release tablet cores of insoluble drugs having sustained-release coating 72 1995
5,811,126 Controlled release matrix for pharmaceuticals 61 1995
5,763,452 Pharmaceutical compositions and usages 32 1996
5,849,240 Method of preparing sustained release pharmaceutical compositions 77 1996
5,891,471 Pharmaceutical multiparticulates 71 1996
5,601,845 Pharmaceutical spheroid formulation 67 1996
5,843,480 Controlled release diamorphine formulation 56 1996
5,879,705 Sustained release compositions of morphine and a method of preparing pharmaceutical compositions 72 1997
5,908,848 Synergistic composition of codine and ibuprofen to treat arthritis 34 1997
5,942,241 Formulations and methods for providing prolonged local anesthesia 96 1997
6,068,855 Pharmaceutical composition containing a fusible carrier and method for producing the same 51 1997
5,965,163 Substained release compositions and a method of preparing pharmaceutical compositions 81 1997
6,077,532 Pharmaceutical ion exchange resin composition 39 1998
6,306,438 Stabilized sustained release tramadol formulations 48 1998
6,399,096 Pharmaceutical formulation 45 1998
6,143,328 Sustained release compositions and a method of preparing pharmaceutical compositions 38 1999
6,162,467 Sustained release compositions and a method of preparing pharmaceutical compositions 57 1999
6,210,714 Immediate release tablet cores of acetaminophen having sustained-release coating 51 2000
6,387,404 Immediate release tablet cores of insoluble drugs having sustained-release coating 53 2001
6,716,449 Controlled-release compositions containing opioid agonist and antagonist 54 2001
6,627,635 Method of preventing abuse of opioid dosage forms 61 2001
 
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (12)
5,472,943 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists 67 1993
5,585,348 Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia 58 1993
5,512,578 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists 78 1994
5,624,932 Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction 38 1995
5,580,876 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 59 1995
5,767,125 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 63 1996
6,096,756 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 55 1998
6,194,382 Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists 37 1999
2001/0006,967 METHOD OF SIMULTANEOUSLY ENHANCING ANALGESIC POTENCY AND ATTENUATING ADVERSE SIDE EFFECTS CAUSED BY TRAMADOL AND OTHER BIMODALLY-ACTING OPIOID AGONISTS 13 1999
6,362,194 Method and simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 23 2000
6,395,705 Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists 33 2001
6,765,010 Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects 29 2002
 
MERCK FROSST CANADA LTD. (10)
5,409,944 Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase 58 1993
5,604,260 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 70 1993
5,436,265 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents 70 1993
5,521,213 Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 82 1994
5,552,422 Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents 89 1995
5,536,752 Phenyl heterocycles as COX-2 inhibitors 66 1995
5,550,142 Phenyl heterocycles as cox-2 inhibitors 72 1995
5,510,368 N-benzyl-3-indoleacetic acids as antiinflammatory drugs 76 1995
5,604,253 N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors 60 1995
5,639,780 N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors 58 1995
 
ALZA CORPORATION (6)
4,200,098 Osmotic system with distribution zone for dispensing beneficial agent 291 1978
4,285,987 Process for manufacturing device with dispersion zone 260 1979
4,573,995 Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine 117 1984
5,236,714 Abusable substance dosage form having reduced abuse potential 73 1988
5,460,826 Morphine therapy 74 1994
5,866,164 Composition and dosage form comprising opioid antagonist 89 1997
 
REGENTS OF THE UNIVERSITY OF MINNESOTA (6)
4,401,672 Non-addictive narcotic antitussive preparation 50 1981
4,730,048 Gut-selective opiates 67 1985
5,352,680 Delta opioid receptor antagonists to block opioid agonist tolerance and dependence 83 1992
5,457,208 Kappa opioid receptor antagonists 61 1993
5,578,725 Delta opioid receptor antagonists 45 1995
5,780,479 Use of opioid antagonists to treat impulse-control disorders 41 1997
 
UNIVERSITY OF CHICAGO, THE (4)
4,719,215 Quaternary derivatives of noroxymorphone which relieve nausea and emesis 69 1986
4,861,781 Quaternary derivatives of noroxymorphone which relieve nausea and emesis 64 1987
5,102,887 Method for reducing emesis and nausea induced by the administration of an emesis causing agent 66 1990
5,972,954 Use of methylnaltrexone and related compounds 76 1997
 
VIRGINIA COMMONWEALTH UNIVERSITY (4)
5,352,683 Method for the treatment of chronic pain 70 1993
5,321,012 Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance 106 1993
5,502,058 Method for the treatment of pain 88 1994
5,556,838 Inhibiting the development of tolerance to and/or dependence on an addictive substance 100 1994
 
CONTRAL CLINICS OY (3)
4,882,335 Method for treating alcohol-drinking response 62 1988
5,096,715 Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist 48 1989
5,086,058 Method for treating alcoholism with nalmefene 60 1990
 
NAPP PHARMACEUTICAL GROUP LIMITED (3)
5,591,452 Controlled release formulation 69 1994
6,326,027 Controlled release formulation 54 1995
6,254,887 Controlled release tramadol 52 1996
 
The Rockefeller University (3)
4,987,136 Method for controlling gastrointestinal dysmotility 98 1986
4,769,372 Method of treating patients suffering from chronic pain or chronic cough 71 1986
4,785,000 Method of treating patients suffering from chronic pain or chronic cough 50 1987
 
BASF AKTIENGESELLSCHAFT (2)
4,806,558 Diarylacetylenes and their use in treating acne 43 1985
4,957,681 Preparation of pharmaceutical mixtures 77 1989
 
E. I. DU PONT DE NEMOURS AND COMPANY (2)
4,451,470 Analgesic, antagonist, and/or anorectic 14-fluoromorphinans 50 1982
5,593,994 Prostaglandin synthase inhibitors 54 1994
 
Eli Lilly and Company (2)
4,293,539 Controlled release formulations and method of treatment 85 1979
5,998,434 Composition for treating pain 37 1998
 
EUROCELTIQUE S.A., 122, BOULEVARD DE LA PETRUSSE, LUXEMBOURG (2)
4,844,909 Controlled release hydromorphone composition 93 1987
4,844,910 Spheroids 42 1987
 
NOVA PHARMACEUTICAL CORPORATION (2)
4,760,069 Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists 53 1985
4,889,860 Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists 57 1987
 
OMEROS CORPORATION (2)
5,858,017 Urologic irrigation solution and method for inhibition of pain, inflammation and spasm 93 1996
5,860,950 Arthroscopic irrigation solution and method for inhibition of pain and inflammation 78 1996
 
PURDUE PHARMA COMPANY, THE (2)
4,861,598 Controlled release bases for pharmaceuticals 113 1986
4,970,075 Controlled release bases for pharmaceuticals 92 1989
 
RECKITT BENCKISER HEALTHCARE (UK) LIMITED (2)
4,582,835 Analgesic compositions 82 1984
4,661,492 Analgesic compositions 57 1985
 
Schaap; Robert J. (2)
5,316,759 Agonist-antagonist combination to reduce the use of nicotine and other drugs 53 1992
5,574,052 Agonist-antagonist combination to reduce the use of nicotine and other drugs 101 1994
 
ADIR ET COMPAGNIE (1)
5,130,311 Oxazolopyridine compounds, compositions and use 38 1991
 
Aminotek Sciences, Inc. (1)
5,256,669 Methods and compositions for treating acute or chronic pain and drug addiction 48 1992
 
BAKER NORTON PHARMACEUTICALS, INC. (1)
4,873,076 Method of safely providing anesthesia or conscious sedation 48 1989
 
BRISTOL-MYERS SQUIBB COMPANY (1)
4,457,933 Prevention of analgesic abuse 78 1981
 
COLMAN PRODUCTS LIMITED (1)
4,935,428 Treating opiate dependence 60 1988
 
DUPONT MERCK PHARMACEUTICAL COMPANY, THE (1)
4,722,928 N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes 18 1985
 
DUPONT PHARMACEUTICALS COMPANY (1)
4,237,140 Analgesic mixture of nalbuphine and acetaminophen 45 1979
 
DYNAGEN, INC. (1)
5,486,362 Controlled, sustained release delivery system for treating drug dependency 80 1993
 
ENCINAL PHARMACEUTICAL INVESTMENTS, LLC (1)
5,869,097 Method of therapy comprising an osmotic caplet 50 1992
 
G. D. Searle & Co. (1)
5,616,601 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation 105 1995
 
GENERAL ELECTRIC COMPANY (1)
5,226,331 Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream 37 1991
 
ICN HUNGARY RT. (1)
5,317,022 Pharmaceutical composition and use 48 1992
 
LIFESHIELD SCIENCES LLC (1)
2004/0158,312 Braided endoluminal device having tapered filaments 3 2003
 
McGinnis; Carolyn (1)
4,608,376 Opiate agonists and antagonists 41 1982
 
MERCK FROSST COMPANY (1)
5,474,995 Phenyl heterocycles as cox-2 inhibitors 140 1994
 
MERCK SHARP & DOHME LTD. (1)
5,880,132 Tachykinin antagonist and an opioid analgesic effective at treating pain or nociception 48 1997
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (1)
5,225,440 Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase 47 1991
 
OREGON, UNIVERSITY OF (1)
5,514,680 Glycine receptor antagonists and the use thereof 55 1993
 
ORTHO-MCNEIL PHARMACEUTICAL, INC. (1)
5,336,691 Composition comprising a tramadol material and acetaminophen and its use 56 1992
 
PEPTECH LIMITED (1)
5,534,492 Muramyl peptide for the treatment of toxicity 38 1995
 
PUREUE PHARMA L.P. (1)
4,834,984 Controlled release dihydrocodeine composition 88 1987
 
RUTGERS, STATE UNIVERSITY OF NEW JERSEY, THE, OLD QUEEN BUILDING, SOMERSET AND GEORGE STREETS, NEW BRUNSWICK, NJ 08903 (1)
4,806,341 Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration 90 1986
 
SCULLY SCOTT MURPHY & PRESSER, PC (1)
5,426,112 Growth regulation and related applications of opioid antagonists 66 1993
 
SIMON, DAVID L. (1)
6,103,258 Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics 35 1998
 
SLOAN-KETTERING INSTITUTE FOR CANCER RES (1)
4,803,208 Opiate agonists and antagonists 45 1985
 
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (1)
4,806,543 Method and compositions for reducing neurotoxic injury 67 1986
 
The Lynx Project Limited (1)
6,310,072 Production of analgesic synergy by co-administration of sub-analgesic doses of a MU opioid agonist and a kappa-2 opioid agonist 34 1997
 
THE MCLEAN HOSPITAL CORPORATION (1)
5,075,341 Treatment for cocaine abuse 103 1989
 
The United States of America as represented by the Secretary of the Army (1)
5,834,477 Opiate analgesic formulation with improved safety 33 1994
 
United Biomedical, Inc. (1)
5,633,259 Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction 40 1995
 
Warner-Lambert Company (1)
5,149,538 Misuse-resistive transdermal opioid dosage form 118 1991
 
YOUNG, JACQUELINE, MS. (1)
5,356,900 Method of treating chronic herpes virus infections using an opiate receptor antagonist 46 1993
 
Other [Check patent profile for assignment information] (7)
4,464,378 Method of administering narcotic antagonists and analgesics and novel dosage forms containing same 126 1981
4,443,428 Extended action controlled release compositions 68 1982
5,376,662 Method of attenuating nerve injury induced pain 43 1993
2004/0092,542 Tamper-resistant oral opioid agonist formulations 23 2003
2005/0095,291 Tamper-resistant oral opioid agonist formulations 33 2003
2005/0181,046 Tamper-resistant oral opioid agonist formulations 23 2003
2006/0039,970 Tamper-resistant oral opioid agonist formulations 15 2003

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
PURDUE PHARMA L.P. (2)
8,105,631 Opioid agonist/antagonist combinations 2 2010
8,673,355 Opioid agonist/antagonist combinations 0 2011
 
EURO-CELTIQUE S.A. (1)
8,518,925 Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) 0 2005

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jan 6, 2014
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 6, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 6, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00